Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2020)

Historic Cash from Financing Activities for Monopar Therapeutics (MNPR) over the last 4 years, with Q3 2020 value amounting to $6.7 million.

  • Monopar Therapeutics' Cash from Financing Activities rose 5081012.72% to $6.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $17.6 million, marking a year-over-year increase of 725267.65%. This contributed to the annual value of $59.3 million for FY2024, which is 282479.61% up from last year.
  • Latest data reveals that Monopar Therapeutics reported Cash from Financing Activities of $6.7 million as of Q3 2020, which was up 5081012.72% from $946404.0 recorded in Q2 2020.
  • Monopar Therapeutics' Cash from Financing Activities' 5-year high stood at $9.4 million during Q4 2019, with a 5-year trough of -$206270.0 in Q4 2018.
  • For the 4-year period, Monopar Therapeutics' Cash from Financing Activities averaged around $2.2 million, with its median value being $727224.0 (2020).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 216249.38% in 2018, then skyrocketed by 5081012.72% in 2020.
  • Monopar Therapeutics' Cash from Financing Activities (Quarter) stood at $10001.0 in 2017, then plummeted by 2162.49% to -$206270.0 in 2018, then soared by 4650.77% to $9.4 million in 2019, then dropped by 28.25% to $6.7 million in 2020.
  • Its Cash from Financing Activities was $6.7 million in Q3 2020, compared to $946404.0 in Q2 2020 and $508044.0 in Q1 2020.